FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955245311> ?p ?o ?g. }

• W2955245311 endingPage "S333" @default.
• W2955245311 startingPage "S333" @default.
• W2955245311 abstract "The aim of this study was to evaluate the cost-effectiveness analysis of NGS panel of ctDNA versus ctDNA EGFR testing in patients with metastatic non-squamous non-small cell lung who lack tissue material for evaluation of oncogenic mutation. A decision model and Markov model was developed in order to estimate the results of diagnostic tests and therefore its clinical and economic impact in the first line treatment. The horizon time was 1 year and the perspective was the private payer perspective in Brazil. The analysis included the target therapies of EGFR, ALK, ROS-1 and BRAF; and the combined therapy of pembrolizumab plus chemotherapy. The first line of treatment was chosen according to the test results and the NCCN guideline. The analysis was conducted in three scenarios that differ in relation to the target therapies incorporated: (1) EGFR and ALK; (2) EGFR, ALK and ROS-1; (3) EGFR, ALK, ROS-1 and BRAF. Clinical outcomes were derived from clinical trials of the therapies included in the study. The direct medical costs were based on CBHPM (Classificação Brasileira Hierarquizada de Procedimentos Médicos) and CMED PF 18% (Câmara de Regulação do Mercado de Medicamentos). The cost of NGS panel of ctDNA assumed in the analysis was 5,000 BRL. The study did not consider the cost of ctDNA EGFR testing because pharmaceutical companies are bearing the cost of the test. In the three scenarios evaluated, the NGS panel of ctDNA has the potential to save respectively: -4,138.67 BRL; -6,245.10 BRL and -5,720.48 BRL in one year. The ICER were: -15.595,77 (BRL/PFS); -21.399,29 (BRL/PFS); -18.006,42 (BRL/PFS). The savings generated with NGS panel of ctDNA are resulted of the lower use of immunotherapy in the first line. In all scenarios the NGS panel demonstrated to be a dominant alternative in comparison to ctDNA EGFR testing." @default.
• W2955245311 created "2019-07-12" @default.
• W2955245311 creator A5017401969 @default.
• W2955245311 creator A5026021779 @default.
• W2955245311 creator A5033507309 @default.
• W2955245311 creator A5046568656 @default.
• W2955245311 date "2019-05-01" @default.
• W2955245311 modified "2023-09-30" @default.
• W2955245311 title "PPM4 COST-EFFECTIVENESS ANALYSIS OF NEXT GENERATION SEQUENCING PANEL OF CIRCULATING TUMOR DNA IN THE DIAGNOSIS OF PATIENT WITH METASTATIC NON-SQUAMOUS NON- SMALL CELL LUNG CANCER IN BRAZIL" @default.
• W2955245311 doi "https://doi.org/10.1016/j.jval.2019.04.1627" @default.
• W2955245311 hasPublicationYear "2019" @default.
• W2955245311 type Work @default.
• W2955245311 sameAs 2955245311 @default.
• W2955245311 citedByCount "2" @default.
• W2955245311 countsByYear W29552453112022 @default.
• W2955245311 crossrefType "journal-article" @default.
• W2955245311 hasAuthorship W2955245311A5017401969 @default.
• W2955245311 hasAuthorship W2955245311A5026021779 @default.
• W2955245311 hasAuthorship W2955245311A5033507309 @default.
• W2955245311 hasAuthorship W2955245311A5046568656 @default.
• W2955245311 hasBestOaLocation W29552453111 @default.
• W2955245311 hasConcept C121608353 @default.
• W2955245311 hasConcept C126322002 @default.
• W2955245311 hasConcept C142724271 @default.
• W2955245311 hasConcept C143998085 @default.
• W2955245311 hasConcept C2776256026 @default.
• W2955245311 hasConcept C2777701055 @default.
• W2955245311 hasConcept C2780057760 @default.
• W2955245311 hasConcept C2780182762 @default.
• W2955245311 hasConcept C2780416959 @default.
• W2955245311 hasConcept C535046627 @default.
• W2955245311 hasConcept C71924100 @default.
• W2955245311 hasConceptScore W2955245311C121608353 @default.
• W2955245311 hasConceptScore W2955245311C126322002 @default.
• W2955245311 hasConceptScore W2955245311C142724271 @default.
• W2955245311 hasConceptScore W2955245311C143998085 @default.
• W2955245311 hasConceptScore W2955245311C2776256026 @default.
• W2955245311 hasConceptScore W2955245311C2777701055 @default.
• W2955245311 hasConceptScore W2955245311C2780057760 @default.
• W2955245311 hasConceptScore W2955245311C2780182762 @default.
• W2955245311 hasConceptScore W2955245311C2780416959 @default.
• W2955245311 hasConceptScore W2955245311C535046627 @default.
• W2955245311 hasConceptScore W2955245311C71924100 @default.
• W2955245311 hasLocation W29552453111 @default.
• W2955245311 hasOpenAccess W2955245311 @default.
• W2955245311 hasPrimaryLocation W29552453111 @default.
• W2955245311 hasRelatedWork W2152429112 @default.
• W2955245311 hasRelatedWork W2767901395 @default.
• W2955245311 hasRelatedWork W2786497694 @default.
• W2955245311 hasRelatedWork W2898071776 @default.
• W2955245311 hasRelatedWork W2987628800 @default.
• W2955245311 hasRelatedWork W3175277114 @default.
• W2955245311 hasRelatedWork W3186122809 @default.
• W2955245311 hasRelatedWork W3206465355 @default.
• W2955245311 hasRelatedWork W3215044659 @default.
• W2955245311 hasRelatedWork W4308399424 @default.
• W2955245311 hasVolume "22" @default.
• W2955245311 isParatext "false" @default.
• W2955245311 isRetracted "false" @default.
• W2955245311 magId "2955245311" @default.
• W2955245311 workType "article" @default.